

Aziza El Harchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8774554/publications.pdf>

Version: 2024-02-01

26
papers

896
citations

567281

15
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

1106
citing authors

#	ARTICLE	IF	CITATIONS
1	The hERG potassium channel and hERG screening for drug-induced torsades de pointes. , 2008, 119, 118-132.		265
2	Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide. Journal of Molecular and Cellular Cardiology, 2015, 86, 42-53.	1.9	55
3	Atrial arrhythmogenicity of KCNJ2 mutations in short QT syndrome: Insights from virtual human atria. PLoS Computational Biology, 2017, 13, e1005593.	3.2	51
4	Ranolazine inhibition of hERG potassium channels: Drug-pore interactions and reduced potency against inactivation mutants. Journal of Molecular and Cellular Cardiology, 2014, 74, 220-230.	1.9	50
5	Proarrhythmia in KCNJ2-linked short QT syndrome: insights from modelling. Cardiovascular Research, 2012, 94, 66-76.	3.8	49
6	I Ks response to protein kinase A-dependent KCNQ1 phosphorylation requires direct interaction with microtubules. Cardiovascular Research, 2008, 79, 427-435.	3.8	47
7	In silico investigation of a KCNQ1 mutation associated with short QT syndrome. Scientific Reports, 2017, 7, 8469.	3.3	44
8	Long-Term Amiodarone Administration Remodels Expression of Ion Channel Transcripts in the Mouse Heart. Circulation, 2004, 110, 3028-3035.	1.6	41
9	Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome. Journal of Molecular and Cellular Cardiology, 2009, 47, 743-747.	1.9	38
10	Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking. Biochemical Pharmacology, 2016, 113, 24-35.	4.4	34
11	Acidosis Impairs the Protective Role of hERG K ⁺ Channels Against Premature Stimulation. Journal of Cardiovascular Electrophysiology, 2010, 21, 1160-1169.	1.7	30
12	Molecular determinants of hERG potassium channel inhibition by disopyramide. Journal of Molecular and Cellular Cardiology, 2012, 52, 185-195.	1.9	30
13	Rabbit, a relevant model for the study of cardiac β_3 -adrenoceptors. Experimental Physiology, 2009, 94, 400-411.	2.0	24
14	Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K ⁺ Channel. PLoS ONE, 2012, 7, e52451.	2.5	23
15	Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition. Physiological Reports, 2013, 1, e00175.	1.7	21
16	Expression of human ERG K channels in the mouse heart exerts anti-arrhythmic activity. Cardiovascular Research, 2005, 65, 128-137.	3.8	19
17	Early ion-channel remodeling and arrhythmias precede hypertrophy in a mouse model of complete atrioventricular block. Journal of Molecular and Cellular Cardiology, 2011, 51, 713-721.	1.9	17
18	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. Frontiers in Cardiovascular Medicine, 2020, 7, 85.	2.4	17

#	ARTICLE	IF	CITATIONS
19	Investigation of hERG1b Influence on hERG Channel Pharmacology at Physiological Temperature. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2018, 9, 92-103.	0.4	10
20	Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration. <i>Physiological Reports</i> , 2014, 2, e12165.	1.7	8
21	Transfer of Rolf S3-S4 Linker to hERG Eliminates Activation Gating but Spares Inactivation. <i>Biophysical Journal</i> , 2009, 97, 1323-1334.	0.5	7
22	Pharmacological activation of the hERG K ⁺ channel for the management of the long QT syndrome: A review. <i>Journal of Arrhythmia</i> , 2022, 38, 554-569.	1.2	7
23	The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine. <i>Physiological Reports</i> , 2020, 8, e14385.	1.7	4
24	hERG potassium channel inhibition by ivabradine requires channel gating. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 87, 126-128.	1.9	2
25	Structure-activity relationship and cardiac safety of 2-aryl-2-(pyridin-2-yl)acetamides as a new class of broad-spectrum anticonvulsants derived from Disopyramide. <i>Bioorganic Chemistry</i> , 2020, 98, 103717.	4.1	2
26	A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?. <i>Therapeutic Advances in Infectious Disease</i> , 2014, 2, 71-72.	1.8	1